NMD Pharma

Biotech · Aarhus, DK

ClC-1 chloride-channel inhibitors to restore muscle function in neuromuscular diseases

Founders

Thomas Holm Pedersen (Denmark · ♂) — A muscle-physiology researcher at Aarhus University who discovered that the ClC-1 muscle chloride channel could be targeted to restore neuromuscular transmission, then spun out NMD Pharma in 2015 to turn that science into treatments, serving as CEO.

Shares the most investors with (number = shared investors):

Date	Round	Amount
Nov 2023	Series B Aarhus biotech NMD Pharma raised a 75M EUR Series B led by Jeito Capital to fund three Phase 2 trials of its lead neuromuscular drug NMD670.	$81M

Tap an investor to see what else they have backed.

Data is community-curated and may be incomplete.